Results indicate an overall response rate of 36.4% and a safety profile consistent with the disease
Therapeutic options for patients with advanced melanoma, especially those who have progressed with the use of checkpoint inhibitors, are limited. Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) enhances the natural defense against cancer and, according to work released at the ASCO 2020 Virtual Annual Meeting, demonstrated lasting responses in highly pretreated melanoma patients.
The Phase II C-144-01 trial, evaluated the efficacy and safety of lifileucel in patients with unresectable metastatic melanoma who progressed with the use of checkpoint inhibitors and BRAF / MEK inhibitors, if mutant BRAFv600. 66 patients were included, whose therapy consisted of a week of lymph node depletion, a single infusion of lifileucel and up to 6 doses of IL-2.
The overall response rate was 36.4% (2 CR, 22 PR) and the disease control rate was 80.3%. The average response time was 1.9 months (range: 1.3-5.6). After a median follow-up of 17.0 months, the median duration of response has not yet been reached.
The adverse event profile was consistent with the underlying advanced disease and the lymphodepletion and IL-2 regimens. These results were obtained in patients with heavily pretreated metastatic melanoma with a high baseline disease burden who progressed on several previous therapies, including anti-PD1 inhibitors and BRAF / MEK, if BRAFv600 mutant.
J Clin Oncol 38: 2020 (suppl; abstr 10006)